P313 Long-term durability and safety of anti-TNF agents compared with change to a different mechanism of action as a second-line biological treatment after first anti-TNF failure in Crohn′s disease: results from the Andalusian CambiaCrohn study
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Crohn's and Colitis"
DOI: 10.1093/ecco-jcc/jjab076.437
Abstract: After failure to a first aTNF agent in Crohn’s disease (CD), a second aTNF shows higher rates of failure and discontinuation. Initiating a therapy with a different mechanism of action (MoA) such as ustekinumab (UST)… read more here.
Keywords: atnf moa; line biological; second line; line ... See more keywords
Is There a Best First Line Biological/Small Molecule in IBD: Are We Ready for Sequencing?
Sign Up to like & getrecommendations! Published in 2022 at "Biomedicines"
DOI: 10.3390/biomedicines10040749
Abstract: Inflammatory bowel disease (IBD) is a chronic, life-long inflammatory condition of the gastrointestinal tract. Treatment strategy depends on the severity of the disease course. IBD physicians need to be aware of the life-long treatment options… read more here.
Keywords: small molecule; biological small; line biological; first line ... See more keywords